New drug for fatty liver disease takes first step in human testing
NCT ID NCT06308874
First seen Jan 03, 2026 · Last updated Jun 20, 2026 · Updated 26 times
Summary
This early-stage trial tested the safety and tolerability of a single dose of J2H-1702 in 16 healthy women. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. Researchers measured how the body processes the drug and its effects, but this study does not yet test if it works against the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
J2H Biotech
Suwon, Gyeonggi-do, 16684, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
J2H-1702
What this could lead to
If successful, this could lead to further studies testing J2H-1702 as a potential treatment for non-alcoholic steatohepatitis (NASH), a liver disease.
What could go wrong
This is a very early Phase 1 trial with only 16 healthy women, not patients. It only tests safety and drug levels, not whether it works for NASH. Many drugs fail at this stage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.